TR201809010T4 - Kanser tedavi yöntemi. - Google Patents

Kanser tedavi yöntemi. Download PDF

Info

Publication number
TR201809010T4
TR201809010T4 TR2018/09010T TR201809010T TR201809010T4 TR 201809010 T4 TR201809010 T4 TR 201809010T4 TR 2018/09010 T TR2018/09010 T TR 2018/09010T TR 201809010 T TR201809010 T TR 201809010T TR 201809010 T4 TR201809010 T4 TR 201809010T4
Authority
TR
Turkey
Prior art keywords
cancer
compound
treatment
compounds
cell
Prior art date
Application number
TR2018/09010T
Other languages
English (en)
Turkish (tr)
Inventor
Connie Erickson-Miller Lynn
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39690807&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201809010(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TR201809010T4 publication Critical patent/TR201809010T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TR2018/09010T 2007-02-16 2008-02-15 Kanser tedavi yöntemi. TR201809010T4 (tr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US89023607P 2007-02-16 2007-02-16
US89255207P 2007-03-02 2007-03-02
US90820507P 2007-03-27 2007-03-27
US94934707P 2007-07-12 2007-07-12
US95228907P 2007-07-27 2007-07-27
US96919207P 2007-08-31 2007-08-31
US97721607P 2007-10-03 2007-10-03

Publications (1)

Publication Number Publication Date
TR201809010T4 true TR201809010T4 (tr) 2018-07-23

Family

ID=39690807

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/09010T TR201809010T4 (tr) 2007-02-16 2008-02-15 Kanser tedavi yöntemi.

Country Status (28)

Country Link
US (2) US20100075928A1 (OSRAM)
EP (1) EP2124547B3 (OSRAM)
JP (1) JP5511391B2 (OSRAM)
KR (1) KR101447763B1 (OSRAM)
CN (1) CN101662937B (OSRAM)
AR (1) AR065348A1 (OSRAM)
AU (1) AU2008216106C1 (OSRAM)
BR (1) BRPI0807940B8 (OSRAM)
CA (1) CA2678358C (OSRAM)
CR (1) CR10997A (OSRAM)
DK (1) DK2124547T6 (OSRAM)
EA (1) EA017715B1 (OSRAM)
ES (1) ES2675070T7 (OSRAM)
FI (1) FI2124547T4 (OSRAM)
HU (1) HUE038563T2 (OSRAM)
IL (2) IL200319A (OSRAM)
MA (1) MA31202B1 (OSRAM)
MX (1) MX2009008822A (OSRAM)
NZ (1) NZ579068A (OSRAM)
PE (1) PE20081784A1 (OSRAM)
PL (1) PL2124547T5 (OSRAM)
PT (1) PT2124547T (OSRAM)
SI (1) SI2124547T2 (OSRAM)
TR (1) TR201809010T4 (OSRAM)
TW (1) TW200906393A (OSRAM)
UY (1) UY30915A1 (OSRAM)
WO (1) WO2008101141A2 (OSRAM)
ZA (1) ZA200905532B (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110129550A1 (en) * 2007-02-16 2011-06-02 Connie Erickson-Miller Cancer treatment method
US20110160130A1 (en) * 2007-02-16 2011-06-30 Connie Erickson-Miller Cancer treatment method
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
EA022915B1 (ru) * 2007-10-09 2016-03-31 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Способы лечения острого миелоидного лейкоза и миелодиспластического синдрома
ES2782898T3 (es) 2009-05-29 2020-09-16 Novartis Ag Métodos de administración de compuestos agonistas de la trombopoyetina
AU2011296047A1 (en) * 2010-09-01 2013-03-21 Novartis Ag Combination of HDAC inhibitors with thrombocytopenia drugs
WO2014150252A1 (en) 2013-03-15 2014-09-25 Ligand Pharmaceuticals Incorporated Methods of treatment associated with the granulocyte colony-stimulating factor receptor
IL295592A (en) * 2016-05-06 2022-10-01 Taris Biomedical Llc A method for treating urothelial cancer in the lower system
RU2675695C1 (ru) * 2018-03-06 2018-12-24 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации Способ лечения рака предстательной железы высокого и очень высокого риска

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559235A (en) * 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) * 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
AP9300587A0 (en) * 1992-11-12 1995-05-05 Glaxo Inc Water soluble camptothecin derivatives.
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) * 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
US6316652B1 (en) * 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
WO1999011262A1 (en) 1997-09-02 1999-03-11 Roche Diagnostics Gmbh Mpl-receptor ligands, process for their preparation, medicaments containing them and their use for the treatment and prevention of thrombocytopaenia and anaemia
CA2380206A1 (en) * 1999-07-26 2001-02-01 Shionogi & Co., Ltd. Pharmaceutical compositions exhibiting thrombopoietin receptor agonism
ES2160560T1 (es) 1999-11-10 2001-11-16 Curacyte Ag Colorantes o,o'-dihidroxi-azoicos como constituyentes de medicamentos para el tratamiento de trombopenias.
CA2390095C (en) * 1999-11-10 2013-01-08 M. Rigdon Lentz Method and system to remove cytokine inhibitor in patients
TWI284639B (en) * 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
CY2010012I2 (el) * 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
WO2001092211A1 (en) 2000-05-30 2001-12-06 Chugai Seiyaku Kabushiki Kaisha Compounds exhibiting thrombopoietin-like activities
US6737062B2 (en) * 2000-05-31 2004-05-18 Genzyme Corporation Immunogenic compositions
ES2236481T3 (es) * 2001-01-16 2005-07-16 Glaxo Group Limited Combinacion farmaceutica que contiene una 4-quinazolinamina y paclitaxel, carboplatino o vinorelbina para el tratamiento de cancer.
US7169931B2 (en) 2001-01-26 2007-01-30 Shionogi & Co., Ltd. Cyclic compounds exhibiting thrombopoietin receptor agonism
BR0206670A (pt) 2001-01-26 2004-02-25 Shionogi & Co Compostos halogenados que exibem agonismo para receptor de trombopoietina
WO2002062775A1 (en) 2001-02-02 2002-08-15 Yamanouchi Pharmaceutical Co., Ltd. 2-acylaminothiazole derivative or its salt
US6613753B2 (en) * 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
AU2002334595B2 (en) * 2001-09-24 2007-03-01 Tosk, Inc. Reduced toxicity cisplatin formulations and methods for using the same
KR101010905B1 (ko) * 2002-01-18 2011-01-25 아스텔라스세이야쿠 가부시키가이샤 2-아실아미노티아졸 유도체 또는 그 염
MY142390A (en) * 2002-05-22 2010-11-30 Glaxosmithkline Llc 3' - [(2z)-[1-(3,4-dimethylphenyl)-1,5- dihydro-3- methyl-5-0xo-4h-pyrazol-4- ylidene]hydrazino]-2' -hydroxy -[1,1' -biphenyl]-3-carboxylic acid bis-(monoethanolamine)
JP4317818B2 (ja) * 2002-09-30 2009-08-19 アステラス製薬株式会社 ２−アシルアミノチアゾール誘導体の新規な塩
WO2004096154A2 (en) 2003-04-29 2004-11-11 Smithkline Beecham Corporation Methods for treating degenerative diseases/injuries
WO2005118551A2 (en) 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
US7314887B2 (en) * 2004-10-25 2008-01-01 Ligand Pharmaceuticals, Inc. Thrombopoietin activity modulating compounds and methods
CA2630234A1 (en) 2005-11-23 2007-05-31 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
AU2007225115A1 (en) 2006-03-15 2007-09-20 Ligand Pharmaceuticals Incorporated Synthesis of thrombopoietin activity modulating compounds

Also Published As

Publication number Publication date
ES2675070T3 (es) 2018-07-06
ES2675070T7 (en) 2025-08-06
TW200906393A (en) 2009-02-16
CN101662937B (zh) 2014-03-12
DK2124547T4 (da) 2025-08-04
PT2124547T (pt) 2018-07-04
KR101447763B1 (ko) 2014-10-07
AR065348A1 (es) 2009-06-03
BRPI0807940A2 (pt) 2013-07-30
PL2124547T3 (pl) 2018-08-31
PL2124547T5 (pl) 2025-08-04
JP5511391B2 (ja) 2014-06-04
DK2124547T3 (en) 2018-07-16
UY30915A1 (es) 2008-09-02
US20100075928A1 (en) 2010-03-25
EP2124547A4 (en) 2010-05-05
MX2009008822A (es) 2009-08-28
AU2008216106B9 (en) 2013-09-05
SI2124547T2 (sl) 2025-07-31
PE20081784A1 (es) 2009-01-25
EP2124547A2 (en) 2009-12-02
KR20090113330A (ko) 2009-10-29
US20090022814A1 (en) 2009-01-22
IL238394B (en) 2018-05-31
FI2124547T4 (fi) 2025-07-29
IL200319A0 (en) 2010-04-29
ZA200905532B (en) 2010-04-28
JP2010519221A (ja) 2010-06-03
EP2124547B1 (en) 2018-03-28
CA2678358C (en) 2015-12-08
CN101662937A (zh) 2010-03-03
WO2008101141A3 (en) 2008-10-16
EA017715B1 (ru) 2013-02-28
AU2008216106B2 (en) 2013-07-11
NZ579068A (en) 2012-05-25
CA2678358A1 (en) 2008-08-21
IL238394A0 (en) 2015-06-30
MA31202B1 (fr) 2010-02-01
HUE038563T2 (hu) 2018-10-29
EP2124547B3 (en) 2025-06-18
AU2008216106C1 (en) 2025-11-13
BRPI0807940B8 (pt) 2021-05-25
DK2124547T6 (da) 2025-09-01
SI2124547T1 (en) 2018-08-31
CR10997A (es) 2009-10-16
WO2008101141A2 (en) 2008-08-21
BRPI0807940B1 (pt) 2020-10-27
IL200319A (en) 2015-05-31
EA200970776A1 (ru) 2010-02-26
AU2008216106A1 (en) 2008-08-21
EP2124547B2 (en) 2025-04-16

Similar Documents

Publication Publication Date Title
TR201809010T4 (tr) Kanser tedavi yöntemi.
AU2010306653B2 (en) Combination
JP6328590B2 (ja) 結晶質ｎ−｛（１ｓ）−２−アミノ−１−［（３−フルオロフェニル）メチル］エチル｝−５−クロロ−４−（４−クロロ−１−メチル−１ｈ−ピラゾール−５−イル）−２−チオフェンカルボキサミド塩酸塩
AU2014325016B2 (en) Combination therapy using azabicyclo compound for cancer
KR20150070393A (ko) 조합물
US20190008855A1 (en) Cancer treatment method
US20120302579A1 (en) Cancer treatment method
US20200276192A1 (en) Cancer treatment method
US20090048318A1 (en) Methods for treating degenerative diseases/injuries
EP1993538A2 (en) Thiazolones for use as pi3 kinase inhibitors